The US Department of Health and Human Services has awarded Pfenex $18.8m contract to support the development of a robust Pfenex Expression Technology based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax. Pursuant to the contract, Pfenex will identify high producing expression strains capable of producing high titers of stable rPA and then develop commercial cGMP manufacturing process.
Xconomy
Wednesday 4 August 2010
Pfenex awarded anthrax tech contract
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment